Nortriptyline for Quitting Smoking: Evidence and Dosing

Nortriptyline for smoking cessation is a second-line option: a tricyclic antidepressant that is licensed for depression, has never been approved by a regulator for quitting smoking, and is used off-label only when a prescriber decides the first-line treatments are unsuitable. The trial evidence is genuinely positive, but it is thin next to the evidence behind varenicline, bupropion and nicotine replacement, and the safety profile is the reason it sits in second place.

What nortriptyline actually is

Nortriptyline is a tricyclic antidepressant, one of the older families of antidepressant drugs that came into use decades before the modern SSRIs. Its US prescribing information gives a single indication: the relief of symptoms of depression. Nothing on the label mentions tobacco, nicotine or quitting.

It works mainly by blocking the reuptake of noradrenaline, and to a lesser extent serotonin, in the brain. That is a different mechanism from bupropion, the licensed antidepressant option, which acts on dopamine and noradrenaline and also has some direct effect at nicotinic receptors. Both are antidepressants; they are not interchangeable.

Because nortriptyline is an old, off-patent generic, no company has had a commercial reason to run the large licensing trials needed to add a cessation indication. That, rather than a failure of the drug, is much of why it sits where it does.

Why it is used off-label for quitting

Two ideas put antidepressants into cessation research in the first place. Nicotine withdrawal can produce a short-term dip in mood that an antidepressant might relieve, and some antidepressants may act directly on the neural pathways that underlie nicotine dependence. The 2023 Cochrane review of antidepressants for smoking cessation sets out both rationales explicitly.

Off-label prescribing is legal and routine, and it is not the same as unsafe or unproven. It means the regulator has not assessed the drug for that use, so the decision sits squarely with the prescriber, who weighs the evidence against your individual risks. For background on why the pull toward a cigarette is so persistent, our explainer on how dependence forms covers the mechanism.

In practice it comes up in three situations: varenicline was tried and not tolerated, bupropion is unsuitable or ineffective, or a depressive illness also needs treating and the clinician wants one medicine working on both fronts. Even then it is a discussion, not a default.

What the evidence shows on abstinence

The best single summary is the Cochrane review Antidepressants for smoking cessation, updated in 2023, which pooled 124 studies and 48,832 participants across the whole drug class. Its headline finding for nortriptyline is that it aided smoking cessation compared with placebo, with a risk ratio of 2.03 and a confidence interval of 1.48 to 2.78, drawn from six studies and 975 participants.

Read that alongside bupropion from the same review and the picture sharpens. Bupropion returned a risk ratio of 1.60, but from 50 studies and 18,577 participants, rated high certainty. Nortriptyline’s larger point estimate rests on a fraction of the data, which is why its confidence interval is so much wider.

Cochrane also compared the two drugs head to head. Bupropion came out ahead of nortriptyline with a risk ratio of 1.30, but the confidence interval ran from 0.93 to 1.82 across just three studies and 417 participants, so that comparison crosses the line of no difference and cannot settle the question. The reviewers’ own wording is careful: nortriptyline appears to have a beneficial effect on quit rates relative to placebo, although bupropion may be more effective.

One more finding is worth knowing if you are quitting with a low mood. Cochrane described the evidence on whether antidepressants help people with current or previous depression more than anyone else as sparse and inconsistent. If depression is part of your picture, our guide to quitting with depression is a better starting point than assuming a drug will handle both.

This recorded seminar from Action on Smoking and Health walks through how stop-smoking medicines are chosen in practice, which is useful background before a prescriber appointment.

What published guidance describes for dosing

Nothing here is a recommendation to you. It describes what published guidance reports, so you recognize the numbers if a prescriber mentions them.

The US Public Health Service clinical practice guideline Treating Tobacco Use and Dependence summarizes the cessation trials it reviewed as using 75 mg per day in three treatment arms and 100 mg per day in two, with treatment lasting from six to 13 weeks. Those trials started the medicine before the quit date rather than on it, because a tricyclic takes time to reach a steady level in the blood.

The licensed depression dosing on the FDA label is different again: a usual adult dose of 25 mg three or four times daily, plasma monitoring in the range of 50 to 150 ng/mL once the daily dose goes above 100 mg, and a statement that doses above 150 mg per day are not recommended. Elderly and adolescent patients are given a lower range of 30 to 50 mg per day.

What matters for you is the shape of the plan rather than the numbers: a starting dose that is deliberately low, a gradual increase, a quit date set some way into treatment, and a planned end point. Setting that date properly makes a measurable difference, which is why we wrote a separate guide on how to set a quit date that sticks. Your prescriber chooses every one of those parameters, and they will also decide how to taper at the end rather than stopping abruptly.

Side effects, warnings and who should avoid it

This is the part that keeps nortriptyline in second place, and it deserves to be read properly rather than skimmed.

Overdose risk. The FDA label for nortriptyline states plainly that deaths may occur from overdose with this class of drugs, and that critical manifestations include cardiac dysrhythmias, severe hypotension, shock, convulsions and central nervous system depression including coma. The label instructs prescribers to write for the smallest quantity of capsules consistent with good patient management, specifically to reduce that risk. Tricyclics are far less forgiving in overdose than the first-line cessation drugs.

Suicidality warning. Nortriptyline carries the antidepressant class warning. Pooled analyses of short-term placebo-controlled trials showed that antidepressants increase the risk of suicidal thinking and behavior in children, adolescents and young adults aged 18 to 24 who have major depressive disorder and other psychiatric disorders. The same analyses showed no increase beyond age 24 and a reduction in adults aged 65 and over. Anyone starting it, and the people around them, should watch for agitation, panic, insomnia, irritability, impulsivity or worsening mood, especially in the first weeks and whenever the dose changes.

Cardiac effects. The label contraindicates nortriptyline during the acute recovery period after a myocardial infarction, and says people with cardiovascular disease should take it only under close supervision because the drug tends to produce sinus tachycardia and to prolong conduction time. Brugada syndrome appears in post-marketing reports.

Anticholinergic and other effects. Great caution is advised with a history of urinary retention. The drug lowers the seizure threshold, and care is needed in hyperthyroid patients or anyone on thyroid medication because arrhythmias may develop. It can impair the alertness needed to drive or operate machinery, and alcohol potentiates its effects. Angle-closure glaucoma appears in post-marketing reports.

Absolute contraindications. Monoamine oxidase inhibitors must not be combined with nortriptyline, and at least 14 days should separate stopping one and starting the other in either direction, because of serotonin syndrome risk. Known hypersensitivity to tricyclics rules it out.

Nortriptyline vs bupropion vs varenicline

The honest summary is that nortriptyline is the option you reach for when the others are off the table, not the one you start with.

In the Cochrane data, bupropion produced inferior quit rates to varenicline, with a risk ratio of 0.73 across nine studies and 7,564 participants. Our side-by-side on varenicline vs bupropion unpacks what that means day to day, and if cytisine is available where you live, the piece on all three quit pills compared adds the fourth option to the table.

The 2008 clinical practice guideline is explicit about why nortriptyline is classified as second-line at all. Second-line medicines have evidence of effectiveness, but a more limited role, because the FDA has not approved them for tobacco dependence and because there are more concerns about potential side effects. Nortriptyline, it notes, has not been evaluated or approved by the FDA as a medication for treating tobacco use and dependence.

Combining nortriptyline with NRT

This comes up constantly, and the answer is genuinely unresolved rather than simply no.

A 2023 network meta-analysis in Addiction Biology found that nortriptyline combined with nicotine replacement therapy beat placebo, with an odds ratio of 2.33 and a confidence interval of 1.21 to 4.47. That tells you the combination works better than nothing. It does not tell you the combination beats nicotine replacement on its own, and earlier Cochrane work concluded there was insufficient evidence that adding nortriptyline to NRT provides an additional long-term benefit.

So if a prescriber suggests running both, that is a defensible clinical judgment rather than a proven upgrade. If nicotine replacement is the part you are unsure about, our comparison of NRT alongside medication covers patch, gum, lozenge and spray in plain terms. Combination NRT, meaning a patch plus a faster-acting product, has its own strong evidence base and is usually the cheaper and safer thing to try first.

How to raise it with your prescriber

You do not need to argue a case. You need to arrive with information that makes the decision easier for both of you. Nortriptyline is prescription-only, so the conversation is the whole route in.

• Say what you have already tried, at what dose, for how long, and why it stopped: side effects, cost, no effect, or you never got started.
• Bring the dates. A record of attempts, relapses and triggers beats a summary from memory.
• List every medicine and supplement you take, including anything from another prescriber. The MAOI interaction is absolute, and several other interactions matter.
• Mention any heart condition, seizure history, urinary retention, glaucoma, thyroid treatment or recent heart attack without waiting to be asked.
• Be honest about alcohol, and about any history of self-harm or overdose. Both change the risk calculation, and the quantity dispensed.
• Ask three questions: what would we be watching for, how long would I stay on it, and how do we stop it safely.

If a first attempt on any medicine has already failed, that is data rather than a verdict. Our restart guide on quitting again after a relapse covers how to fold what you learned into the next attempt.

The one thing you can do before the appointment is turn vague recollection into a record. In the free iQuit app you can log cravings with their trigger and intensity and keep a daily mood journal, so when you sit down with a prescriber you can show what your worst hours actually look like and what changed week to week. That is the sort of detail a medication review runs on.

Frequently asked questions

This article is general information, not medical advice. Nortriptyline is a prescription-only medicine and is not licensed for smoking cessation. Talk to a doctor or pharmacist before starting, changing or stopping any medication. Further reading: MedlinePlus on nortriptyline and the full FDA prescribing information.